Showing results (111-120 of 125) with videos related to
Sort By:
Pageof 13
Journal of Medicinal Chemistry|December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D InhibitorXiaolun Wang, Shelley Allen, James F Blake, et al.Nature Medicine|October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitorJill Hallin, Vickie Bowcut, Andrew Calinisan, et al.Journal of Medicinal Chemistry|March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant ProteinJohn M Ketcham, Stephen J Harwood, Ruth Aranda, et al.ACS Medicinal Chemistry Letters|January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo ActivityJay B Fell, John P Fischer, Brian R Baer, et al.Molecular Cancer Therapeutics|June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide LoadingNiranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.Cancer Discovery|August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted CancerLars D Engstrom, Ruth Aranda, Laura Waters, et al.Cancer Discovery|November 10, 2022
Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal CancerRona Yaeger, Riccardo Mezzadra, Jenna Sinopoli, et al.The New England Journal of Medicine|October 29, 2010
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerEunice L Kwak, Yung-Jue Bang, D Ross Camidge, et al.Nature Medicine|March 27, 2018
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancerAmritha Nair, Hsiang-Ching Chung, Tingting Sun, et al.Cancer Cell|February 25, 2024
Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancerXinyuan Tong, Ayushi S Patel, Eejung Kim, et al.Pageof 13